Roth Capital Weighs in on Orthofix Medical Inc.’s Q1 2025 Earnings (NASDAQ:OFIX)

Orthofix Medical Inc. (NASDAQ:OFIX) – Equities research analysts at Roth Capital issued their Q1 2025 earnings estimates for Orthofix Medical in a research report issued on Monday, May 6th. Roth Capital analyst J. Wittes anticipates that the medical device company will post earnings of ($0.25) per share for the quarter. The consensus estimate for Orthofix Medical’s current full-year earnings is ($1.51) per share. Roth Capital also issued estimates for Orthofix Medical’s Q2 2025 earnings at ($0.04) EPS, Q3 2025 earnings at ($0.04) EPS and Q4 2025 earnings at $0.15 EPS.

Orthofix Medical (NASDAQ:OFIX) last announced its earnings results on Tuesday, March 5th. The medical device company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.01. The company had revenue of $200.42 million for the quarter. Orthofix Medical had a negative net margin of 20.28% and a negative return on equity of 10.63%.

OFIX has been the topic of a number of other research reports. JMP Securities reiterated a “market perform” rating on shares of Orthofix Medical in a report on Monday, April 22nd. Roth Mkm upped their price objective on shares of Orthofix Medical from $12.00 to $15.00 and gave the company a “neutral” rating in a research note on Thursday, March 7th. Finally, StockNews.com lowered shares of Orthofix Medical from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. One research analyst has rated the stock with a sell rating and four have given a hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $15.50.

Orthofix Medical Stock Up 3.2 %

NASDAQ:OFIX opened at $13.89 on Tuesday. Orthofix Medical has a 1-year low of $9.57 and a 1-year high of $21.60. The firm has a market capitalization of $519.62 million, a price-to-earnings ratio of -3.36 and a beta of 1.06. The company has a current ratio of 2.54, a quick ratio of 1.20 and a debt-to-equity ratio of 0.19. The business’s fifty day moving average price is $13.63 and its 200 day moving average price is $13.02.

Institutional Investors Weigh In On Orthofix Medical

A number of institutional investors have recently bought and sold shares of the business. Gladius Capital Management LP grew its stake in shares of Orthofix Medical by 55.2% in the 4th quarter. Gladius Capital Management LP now owns 2,841 shares of the medical device company’s stock valued at $38,000 after purchasing an additional 1,010 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Orthofix Medical by 30.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,516 shares of the medical device company’s stock valued at $101,000 after acquiring an additional 1,752 shares during the period. State Board of Administration of Florida Retirement System bought a new position in shares of Orthofix Medical during the third quarter valued at $130,000. Teza Capital Management LLC acquired a new stake in shares of Orthofix Medical in the 3rd quarter valued at $133,000. Finally, Arizona State Retirement System bought a new stake in shares of Orthofix Medical in the 4th quarter worth about $138,000. Institutional investors and hedge funds own 89.76% of the company’s stock.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.